The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic ...

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

Dec. 3, 2024 — A special protein can play a key role in the fight against certain types of prostate cancer. Until now, treatments have involved blocking the protein in question that builds a so ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

In the latest installment of Healio’s video series with ASGE, Fiyinfoluwa O. Abraham, MD, discusses ethnic and racial disparities observed in the incidence of pancreatic cancer, demonstrating the need ...

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Actuate Therapeutics' elraglusib shows promise for pancreatic cancer, but financial instability and risks make it a high-risk ...

More than 700 oncologists, cancer researchers and advocates will converge on the Crescent City this week as part of the 2025 NeauxCancer Conference. The event got its start four years ago by the ...